Identification of α-enolase as an autoantigen in lung cancer: Its overexpression is associated with clinical outcomes

Gee Chen Chang, Ko Jiunn Liu, Chia Ling Hsieh, Tsai Shu Hu, Suparat Charoenfuprasert, Hsiung Kun Liu, Kwen Tay Luh, Li Han Hsu, Chew Wen Wu, Chou Chik Ting, Chih Yi Chen, Kun Chieh Chen, Tsung Ying Yang, Teh Ying Chou, Wen Hua Wang, Jacqueline Whang-Peng, Neng Yao Shih

研究成果: 雜誌貢獻文章

104 引文 (Scopus)

摘要

Purpose: Although existence of humoral immunity has been previously shown in malignant pleural effusions, only a limited number of immunogenic tumor-associated antigens (TAA) have been identified and associated with lung cancer. In this study, we intended to identify moreTAAs in pleural effusion - derived tumor cells. Experimental Design: Using morphologically normal lung tissues as a control lysate in Western blotting analyses, 54 tumor samples were screened with autologous effusion antibodies. Biochemical purification and mass spectrometric identification of TAAs were done using established effusion tumor cell lines as antigen sources. We identified a p48 antigen as α-enolase (ENO1). Semiquantitative immunohistochemistry was used to evaluate expression status of ENO1 in the tissue samples of 80 patients with non-small cell lung cancer (NSCLC) and then correlated with clinical variables. Results: Using ENO1-specifc antiserum, up-regulation of ENO1 expression in effusion tumor cells from 11 of 17 patients was clearly observed compared with human normal lung primary epithelial and non-cancer-associated effusion cells. Immunohistochemical studies consistently showed high level of ENO1 expression in all the tumors we have examined thus far. Log-rank and Cox's analyses of ENO1 expression status revealed that its expression level in primary tumors was a key factor contributing to overall- and progression-free survivals of patients (P <0.05). The same result was also obtained in the early stage of NSCLC patients, showing that tumors expressing relatively higher ENO1 level were tightly correlated with poorer survival outcomes. Conclusions: Our data strongly support a prognostic role of ENO1 in determining tumor malignancy of patients with NSCLC.
原文英語
頁(從 - 到)5746-5754
頁數9
期刊Clinical Cancer Research
12
發行號19
DOIs
出版狀態已發佈 - 十月 1 2006
對外發佈Yes

指紋

Phosphopyruvate Hydratase
Autoantigens
Lung Neoplasms
Neoplasms
Non-Small Cell Lung Carcinoma
Malignant Pleural Effusion
Antigens
Lung
Neoplasm Antigens
Pleural Effusion
Humoral Immunity
Tumor Cell Line
Disease-Free Survival
Immune Sera
Research Design
Up-Regulation
Western Blotting
Immunohistochemistry
Survival
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

引用此文

Identification of α-enolase as an autoantigen in lung cancer : Its overexpression is associated with clinical outcomes. / Chang, Gee Chen; Liu, Ko Jiunn; Hsieh, Chia Ling; Hu, Tsai Shu; Charoenfuprasert, Suparat; Liu, Hsiung Kun; Luh, Kwen Tay; Hsu, Li Han; Wu, Chew Wen; Ting, Chou Chik; Chen, Chih Yi; Chen, Kun Chieh; Yang, Tsung Ying; Chou, Teh Ying; Wang, Wen Hua; Whang-Peng, Jacqueline; Shih, Neng Yao.

於: Clinical Cancer Research, 卷 12, 編號 19, 01.10.2006, p. 5746-5754.

研究成果: 雜誌貢獻文章

Chang, GC, Liu, KJ, Hsieh, CL, Hu, TS, Charoenfuprasert, S, Liu, HK, Luh, KT, Hsu, LH, Wu, CW, Ting, CC, Chen, CY, Chen, KC, Yang, TY, Chou, TY, Wang, WH, Whang-Peng, J & Shih, NY 2006, 'Identification of α-enolase as an autoantigen in lung cancer: Its overexpression is associated with clinical outcomes', Clinical Cancer Research, 卷 12, 編號 19, 頁 5746-5754. https://doi.org/10.1158/1078-0432.CCR-06-0324
Chang, Gee Chen ; Liu, Ko Jiunn ; Hsieh, Chia Ling ; Hu, Tsai Shu ; Charoenfuprasert, Suparat ; Liu, Hsiung Kun ; Luh, Kwen Tay ; Hsu, Li Han ; Wu, Chew Wen ; Ting, Chou Chik ; Chen, Chih Yi ; Chen, Kun Chieh ; Yang, Tsung Ying ; Chou, Teh Ying ; Wang, Wen Hua ; Whang-Peng, Jacqueline ; Shih, Neng Yao. / Identification of α-enolase as an autoantigen in lung cancer : Its overexpression is associated with clinical outcomes. 於: Clinical Cancer Research. 2006 ; 卷 12, 編號 19. 頁 5746-5754.
@article{2bd7ef3a43834e3ab1e2e518a9dca972,
title = "Identification of α-enolase as an autoantigen in lung cancer: Its overexpression is associated with clinical outcomes",
abstract = "Purpose: Although existence of humoral immunity has been previously shown in malignant pleural effusions, only a limited number of immunogenic tumor-associated antigens (TAA) have been identified and associated with lung cancer. In this study, we intended to identify moreTAAs in pleural effusion - derived tumor cells. Experimental Design: Using morphologically normal lung tissues as a control lysate in Western blotting analyses, 54 tumor samples were screened with autologous effusion antibodies. Biochemical purification and mass spectrometric identification of TAAs were done using established effusion tumor cell lines as antigen sources. We identified a p48 antigen as α-enolase (ENO1). Semiquantitative immunohistochemistry was used to evaluate expression status of ENO1 in the tissue samples of 80 patients with non-small cell lung cancer (NSCLC) and then correlated with clinical variables. Results: Using ENO1-specifc antiserum, up-regulation of ENO1 expression in effusion tumor cells from 11 of 17 patients was clearly observed compared with human normal lung primary epithelial and non-cancer-associated effusion cells. Immunohistochemical studies consistently showed high level of ENO1 expression in all the tumors we have examined thus far. Log-rank and Cox's analyses of ENO1 expression status revealed that its expression level in primary tumors was a key factor contributing to overall- and progression-free survivals of patients (P <0.05). The same result was also obtained in the early stage of NSCLC patients, showing that tumors expressing relatively higher ENO1 level were tightly correlated with poorer survival outcomes. Conclusions: Our data strongly support a prognostic role of ENO1 in determining tumor malignancy of patients with NSCLC.",
author = "Chang, {Gee Chen} and Liu, {Ko Jiunn} and Hsieh, {Chia Ling} and Hu, {Tsai Shu} and Suparat Charoenfuprasert and Liu, {Hsiung Kun} and Luh, {Kwen Tay} and Hsu, {Li Han} and Wu, {Chew Wen} and Ting, {Chou Chik} and Chen, {Chih Yi} and Chen, {Kun Chieh} and Yang, {Tsung Ying} and Chou, {Teh Ying} and Wang, {Wen Hua} and Jacqueline Whang-Peng and Shih, {Neng Yao}",
year = "2006",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-06-0324",
language = "English",
volume = "12",
pages = "5746--5754",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Identification of α-enolase as an autoantigen in lung cancer

T2 - Its overexpression is associated with clinical outcomes

AU - Chang, Gee Chen

AU - Liu, Ko Jiunn

AU - Hsieh, Chia Ling

AU - Hu, Tsai Shu

AU - Charoenfuprasert, Suparat

AU - Liu, Hsiung Kun

AU - Luh, Kwen Tay

AU - Hsu, Li Han

AU - Wu, Chew Wen

AU - Ting, Chou Chik

AU - Chen, Chih Yi

AU - Chen, Kun Chieh

AU - Yang, Tsung Ying

AU - Chou, Teh Ying

AU - Wang, Wen Hua

AU - Whang-Peng, Jacqueline

AU - Shih, Neng Yao

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Purpose: Although existence of humoral immunity has been previously shown in malignant pleural effusions, only a limited number of immunogenic tumor-associated antigens (TAA) have been identified and associated with lung cancer. In this study, we intended to identify moreTAAs in pleural effusion - derived tumor cells. Experimental Design: Using morphologically normal lung tissues as a control lysate in Western blotting analyses, 54 tumor samples were screened with autologous effusion antibodies. Biochemical purification and mass spectrometric identification of TAAs were done using established effusion tumor cell lines as antigen sources. We identified a p48 antigen as α-enolase (ENO1). Semiquantitative immunohistochemistry was used to evaluate expression status of ENO1 in the tissue samples of 80 patients with non-small cell lung cancer (NSCLC) and then correlated with clinical variables. Results: Using ENO1-specifc antiserum, up-regulation of ENO1 expression in effusion tumor cells from 11 of 17 patients was clearly observed compared with human normal lung primary epithelial and non-cancer-associated effusion cells. Immunohistochemical studies consistently showed high level of ENO1 expression in all the tumors we have examined thus far. Log-rank and Cox's analyses of ENO1 expression status revealed that its expression level in primary tumors was a key factor contributing to overall- and progression-free survivals of patients (P <0.05). The same result was also obtained in the early stage of NSCLC patients, showing that tumors expressing relatively higher ENO1 level were tightly correlated with poorer survival outcomes. Conclusions: Our data strongly support a prognostic role of ENO1 in determining tumor malignancy of patients with NSCLC.

AB - Purpose: Although existence of humoral immunity has been previously shown in malignant pleural effusions, only a limited number of immunogenic tumor-associated antigens (TAA) have been identified and associated with lung cancer. In this study, we intended to identify moreTAAs in pleural effusion - derived tumor cells. Experimental Design: Using morphologically normal lung tissues as a control lysate in Western blotting analyses, 54 tumor samples were screened with autologous effusion antibodies. Biochemical purification and mass spectrometric identification of TAAs were done using established effusion tumor cell lines as antigen sources. We identified a p48 antigen as α-enolase (ENO1). Semiquantitative immunohistochemistry was used to evaluate expression status of ENO1 in the tissue samples of 80 patients with non-small cell lung cancer (NSCLC) and then correlated with clinical variables. Results: Using ENO1-specifc antiserum, up-regulation of ENO1 expression in effusion tumor cells from 11 of 17 patients was clearly observed compared with human normal lung primary epithelial and non-cancer-associated effusion cells. Immunohistochemical studies consistently showed high level of ENO1 expression in all the tumors we have examined thus far. Log-rank and Cox's analyses of ENO1 expression status revealed that its expression level in primary tumors was a key factor contributing to overall- and progression-free survivals of patients (P <0.05). The same result was also obtained in the early stage of NSCLC patients, showing that tumors expressing relatively higher ENO1 level were tightly correlated with poorer survival outcomes. Conclusions: Our data strongly support a prognostic role of ENO1 in determining tumor malignancy of patients with NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=33750285970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750285970&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-0324

DO - 10.1158/1078-0432.CCR-06-0324

M3 - Article

C2 - 17020980

AN - SCOPUS:33750285970

VL - 12

SP - 5746

EP - 5754

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -